29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
May 2024 in “News Digital Object Group”
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
2 citations
,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
6 citations
,
October 1993 in “Endocrinology” Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
December 2021 in “Daehanhanuihakoeji” The traditional herbal formulas Yongdamsagan-Tang and Paljung-san, along with the drug finasteride, can reduce inflammation and may work together without affecting each other's effectiveness against benign prostatic hyperplasia.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
May 2024 in “Clinical and experimental optometry” 1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
Cadd4 effectively reduces cholesterol levels without side effects.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
27 citations
,
July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology” The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men increases the risk of sexual dysfunction.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
April 2007 in “The Journal of Urology” Finasteride reduces bleeding risk during prostate surgery.
6 citations
,
May 2023 in “Molecules” Cepharanthine dry powder inhalers may effectively treat acute lung injury by reducing inflammation.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
35 citations
,
January 2002 in “Scandinavian Journal of Urology and Nephrology” Finasteride reduces prostate bleeding by affecting blood vessel growth.
June 2018 in “The Journal of Sexual Medicine” Low-intensity shock wave therapy is effective in treating erectile dysfunction in diabetic patients.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
November 2023 in “The Journal of Urology” The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.